RHEO down another 15% (after losing 70% in one day on Feb 3) based on a CC this morning about the failed trial. Essentially, they said that if they throw out all the bad data then the results become statsig. Not exactly an original argument.
Even after granting the above, for the sake of discussion, the clinical significance of the rheopheresis procedure is unimpressive: the mean gain in visual acuity relative to baseline for treated patients was only 0.8 lines.
Market Data 
Markets 
AI
